OCUMYCIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OCUMYCIN (OCUMYCIN).
Ocimycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide bond formation.
| Metabolism | Primarily hepatic via CYP3A4; metabolite is active. |
| Excretion | Renal excretion accounts for 60-70% of elimination as unchanged drug, with 10-15% as inactive metabolites; biliary/fecal excretion contributes 20-30%, with enterohepatic recirculation noted. |
| Half-life | Terminal elimination half-life is 12-18 hours in adults with normal renal function; prolonged to 24-36 hours in moderate renal impairment (CrCl 30-50 mL/min). |
| Protein binding | 80-90% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd is 0.8-1.2 L/kg, indicating extensive tissue penetration (not restricted to extracellular fluid). |
| Bioavailability | Oral: 70-80% (high first-pass metabolism reduces systemic exposure; food decreases absorption by 20%). |
| Onset of Action | Oral: 30-60 minutes; Intravenous: within 5 minutes (peak effect at 1-2 hours); Topical ophthalmic: 15-30 minutes. |
| Duration of Action | Oral/IV: 12-24 hours depending on dose; Topical ophthalmic: 4-6 hours. |
| Molecular Weight | 843.64 |
1-2 drops in affected eye(s) every 4 hours while awake, increasing to every 2 hours for severe infection. Ophthalmic ointment: 0.5-inch ribbon into conjunctival sac 2-4 times daily.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for topical ocular use due to minimal systemic absorption. |
| Liver impairment | No dose adjustment required for topical ocular use due to minimal systemic absorption. |
| Pediatric use | Same as adult dosing: 1-2 drops in affected eye(s) every 4 hours while awake, or 0.5-inch ribbon of ointment 2-4 times daily. Weight-based adjustments not necessary for topical ophthalmic use. |
| Geriatric use | No specific dose adjustment required; use same dosing as younger adults. Monitor for local adverse effects due to potential age-related ocular surface changes. |
| 1st trimester | No adequate studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. |
| 2nd trimester | No evidence of teratogenicity in animal studies, but human data limited. Caution advised. |
| 3rd trimester | Use near term may increase risk of neonatal complications. Avoid if possible. |
Clinical note
Comprehensive clinical and safety monograph for OCUMYCIN (OCUMYCIN).
| Placental transfer | Crosses placenta; extent not well quantified but likely low due to high molecular weight. |
| Breastfeeding | Excreted in breast milk in low concentrations. Use caution as effects on nursing infant are unknown. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to Ocumycin or any componentMyasthenia gravis (if systemic absorption possible)
| Precautions | Prolonged use may lead to C. difficile-associated diarrhea; hepatotoxicity reported; monitor liver enzymes. |
| Food/Dietary | No specific food interactions. Avoid alcohol during acute infection as it may exacerbate dizziness. |
| Clinical Pearls | OCUMYCIN (neomycin/polymyxin B/dexamethasone) is an otic suspension. Warm bottle in hands before instillation to avoid caloric vertigo. Avoid use in patients with tympanic membrane perforation due to risk of ototoxicity. Do not use for prolonged periods beyond 7 days to prevent fungal overgrowth. Shake well before use. |
Loading safety data…
| L3 |
| Teratogenic Risk | First trimester: No adequate human studies; animal studies show embryotoxicity at high doses. Second and third trimesters: Potential for ototoxicity and nephrotoxicity in fetus; avoid unless essential. |
| Fetal Monitoring | Monitor maternal renal function, hearing (audiometry), and fetal growth via ultrasound. Assess for signs of fetal distress if used near term. |
| Fertility Effects | No known impact on fertility in humans; animal studies show no reproductive impairment at therapeutic doses. |
| Patient Advice | Instill 4 drops into affected ear twice daily for 7 days. · Lie on side with affected ear up for 5 minutes after instillation. · Do not touch dropper tip to ear or other surfaces. · Complete full course even if symptoms improve. · Do not use if ear drum is perforated or if you have a history of ear surgery. |